Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Model-based Strategy to Guide the Choice of Clinical Doses for ADC
Posted on October 14th, 2020 by Xuanyan Xu in Pharma R&D
Chemotherapy has been a powerful method for fighting cancer for decades. One of the most effective therapies available, it is also known for weakening the patient and causing harsh side effects like pain, nausea, and hair loss. This is because in its zeal to attack cancer cells, chemo also kills healthy cells.
Enter antibody-drug conjugates (ADCs). This promising anti-cancer therapy is designed to specifically target tumor cells, leaving the body’s healthy cells unharmed. Developing safe and effective ADCs is not without its difficulties, though, and more of those challenges need to be overcome before ADCs can replace the role of chemotherapy.
Pharmacokinetic-pharmacodynamic (PKPD) scientists at the French pharmaceutical multinational Pierre Fabre are doing their part. They have developed novel modelling and simulation-based tools to guide the choice of the most promising safe and efficacious dosing regimen of an innovative antibody drug conjugate.
On October 27, Dr. Julie Desrivot Quénelle, PKPD Project Lead at Pierre Fabre, will give a presentation on her team’s work in a free webinar titled “Model-based strategy to guide the choice of clinical doses for ADC,” hosted by Olivier Barberan, Director of Translational Medicine Solutions at Elsevier. It’s a great opportunity to learn more about this important area of cancer research.
To join the webinar, register here.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Sr. Marketing Manager, Life Sciences Audience at Elsevier
- Predicting Cancer Drug Combinations That Work
- Finding Support and Success Along the Development Path
- Cancer-killing combo: Viagra and the flu vaccine
- Extreme Makeover: Clinical Trials Edition
- Seeking Other Perspectives to Tease Out New Innovations